Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.54 USD | +12.74% | +16.45% | -23.04% |
04-18 | NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq | MT |
04-18 | Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 36.89M 2.95B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.59% |
Latest transcript on NRx Pharmaceuticals, Inc.
1 day | +12.74% | ||
1 week | +16.45% | ||
Current month | -24.98% | ||
1 month | -33.21% | ||
3 months | -7.38% | ||
6 months | +15.88% | ||
Current year | -23.04% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Willard
CEO | Chief Executive Officer | 63 | 11/07/22 |
Jonathan Javitt
FOU | Founder | 67 | 17/09/17 |
Richard Narido
DFI | Director of Finance/CFO | 46 | 12/09/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jonathan Javitt
FOU | Founder | 67 | 17/09/17 |
Stephen Willard
CEO | Chief Executive Officer | 63 | 11/07/22 |
Janet Rehnquist
BRD | Director/Board Member | - | 12-26 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 3.54 | +12.74% | 280,114 |
25/04/24 | 3.14 | +0.64% | 102,032 |
24/04/24 | 3.12 | +2.30% | 97,946 |
23/04/24 | 3.05 | +1.67% | 106,468 |
22/04/24 | 3 | -1.32% | 211,625 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.04% | 36.89M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- BRPA Stock